Dupixent®(dupilumab) Phase 3 trial shows positive results in children 1 to 11 years of age with eosinophilic esophagitis First and...
• Phase 1 dose-escalation study started at clinical sites in the U.S. • Milestone demonstrates CureVac’s and GSK’s continued execution...
∙ The RNA Printer® is CureVac’s integrated and automated manufacturing solution for RNA vaccines and therapeutics ∙ CureVac RNA Printer...
Rolling submission to accelerate time to marketing authorization of CVnCoV in SwitzerlandReview process started with submission of first CVnCoV data...
Lessons from the most important tech adoption of our century: the COVID-19 vaccine By Cameron Turner, VP Data Science and...
Data provided further evidence on immunogenicity and protective efficacy of CVnCoV ∙ Induction of robust antibody and T cell responses...